Cargando…

Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis

OBJECTIVES: The aim of this study was to determine the safety and efficacy of the nucleoside analog GS-441524 for cats suffering from various forms of naturally acquired feline infectious peritonitis (FIP). METHODS: Cats ranged from 3.4–73 months of age (mean 13.6 months); 26 had effusive or dry-to-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pedersen, Niels C, Perron, Michel, Bannasch, Michael, Montgomery, Elizabeth, Murakami, Eisuke, Liepnieks, Molly, Liu, Hongwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435921/ https://www.ncbi.nlm.nih.gov/pubmed/30755068 http://dx.doi.org/10.1177/1098612X19825701

Ejemplares similares

The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies
por: Murphy, B.G., et al.
Publicado: (2018)

Antiviral treatment using the adenosine nucleoside analogue GS‐441524 in cats with clinically diagnosed neurological feline infectious peritonitis
por: Dickinson, Peter J., et al.
Publicado: (2020)

Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524
por: Krentz, Daniela, et al.
Publicado: (2021)

Fecal Feline Coronavirus RNA Shedding and Spike Gene Mutations in Cats with Feline Infectious Peritonitis Treated with GS-441524
por: Meli, Marina L., et al.
Publicado: (2022)

Efficacy of Oral Remdesivir Compared to GS-441524 for Treatment of Cats with Naturally Occurring Effusive Feline Infectious Peritonitis: A Blinded, Non-Inferiority Study
por: Cosaro, Emma, et al.
Publicado: (2023)

Thirty‐two cats with effusive or non‐effusive feline infectious peritonitis treated with a combination of remdesivir and GS‐441524
por: Green, Jodie, et al.
Publicado: (2023)

Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS‐441524
por: Coggins, Sally J., et al.
Publicado: (2023)

Nucleoside analog GS‐441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid‐19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2022)

In vitro antiviral effects of GS-441524 and itraconazole combination against feline infectious peritonitis virus
por: Doki, Tomoyoshi, et al.
Publicado: (2022)

An efficient synthesis of RNA containing GS-441524: the nucleoside precursor of remdesivir
por: Moorthy, Ramkumar, et al.
Publicado: (2021)

Clinical Follow-Up and Postmortem Findings in a Cat That Was Cured of Feline Infectious Peritonitis with an Oral Antiviral Drug Containing GS-441524
por: Krentz, Daniela, et al.
Publicado: (2022)

Unlicensed Molnupiravir is an Effective Rescue Treatment Following Failure of Unlicensed GS-441524-like Therapy for Cats with Suspected Feline Infectious Peritonitis
por: Roy, Meagan, et al.
Publicado: (2022)

Unlicensed GS-441524-Like Antiviral Therapy Can Be Effective for at-Home Treatment of Feline Infectious Peritonitis
por: Jones, Sarah, et al.
Publicado: (2021)

Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
por: Yan, Victoria C., et al.
Publicado: (2020)

An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats
por: Cook, Sarah, et al.
Publicado: (2022)

Synthesis and anti-SARS-CoV-2 activity of deuterated GS-441524 analogs
por: Zheng, Wei, et al.
Publicado: (2022)

Effect of GS-441524 in combination with the 3C-like protease inhibitor GC376 on the treatment of naturally transmitted feline infectious peritonitis
por: Lv, Jinbao, et al.
Publicado: (2022)

Comparative Evaluation of GS-441524, Teriflunomide, Ruxolitinib, Molnupiravir, Ritonavir, and Nirmatrelvir for In Vitro Antiviral Activity against Feline Infectious Peritonitis Virus
por: Barua, Subarna, et al.
Publicado: (2023)

Pharmacokinetics of Orally Administered GS-441524 in Dogs
por: Yan, Victoria C., et al.
Publicado: (2021)

Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro
por: Brunotte, Linda, et al.
Publicado: (2021)

Quantification of GS-441524 concentration in feline plasma using high performance liquid chromatography with fluorescence detection
por: Kimble, Benjamin, et al.
Publicado: (2023)

Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment
por: Xie, Jiashu, et al.
Publicado: (2021)

GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses
por: Lo, Michael K., et al.
Publicado: (2017)

Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)
por: Lo, Michael K., et al.
Publicado: (2021)

Practical and Highly Efficient Synthesis of Remdesivir from GS-441524
por: Hu, Tianwen, et al.
Publicado: (2022)

Broad-Spectrum In Vitro Antiviral Activity of ODBG-P-RVn: An Orally-Available, Lipid-Modified Monophosphate Prodrug of Remdesivir Parent Nucleoside (GS-441524)
por: Lo, Michael K., et al.
Publicado: (2021)

Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
por: Amirian, E. Susan, et al.
Publicado: (2020)

Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses
por: Zhou, Qifan, et al.
Publicado: (2023)

Genetic susceptibility to feline infectious peritonitis in Birman cats
por: Golovko, Lyudmila, et al.
Publicado: (2013)

Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients
por: Leegwater, E., et al.
Publicado: (2022)

Exploration of the optimal GS-441524 trough concentration for treating COVID-19
por: Nakano, Yuki, et al.
Publicado: (2023)

Transplacental transfer of Remdesivir and GS‐441524: An ex vivo perfusion study
por: Louchet, Margaux, et al.
Publicado: (2023)

Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2
por: Wei, Daibao, et al.
Publicado: (2021)

Characterization of peritoneal cells from cats with experimentally-induced feline infectious peritonitis (FIP) using RNA-seq
por: Watanabe, Rie, et al.
Publicado: (2018)

Cellular Uptake and Intracellular Phosphorylation of GS-441524: Implications for Its Effectiveness against COVID-19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2021)

Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats
por: Yang, Ling, et al.
Publicado: (2022)

Treatment of cats with feline infectious peritonitis
por: Hartmann, Katrin, et al.
Publicado: (2008)

Significance of Coronavirus Mutants in Feces and Diseased Tissues of Cats Suffering from Feline Infectious Peritonitis
por: Pedersen, Niels C., et al.
Publicado: (2009)

Removal of Remdesivir’s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19
por: Lê, Minh Patrick, et al.
Publicado: (2020)

Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
por: Cox, Robert M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5re538r2g9cqugpjlfhmeshcid